

Cirrhosis and Liver Disease

REFERENCES

- Aleynik SI, Lieber CS. Polyenylphosphatidylcholine corrects the alcohol-induced hepatic oxidative stress by restoring s-adenosylmethionine. *Alcohol*. 2003 May-Jun;38(3):208–12.
- Alwayn IP, Gura K, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. *Pediatr Res*. 2005 Mar;57(3):445–52.
- Barham JB, Edens MB, et al. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. *J Nutr*. 2000 Aug;130(8):1925–31.
- Batakov EA. Effect of Silybum marianum oil and legalon on lipid peroxidation and liver antioxidant systems in rats intoxicated with carbon tetrachloride. *Eksp Klin Farmakol*. 2001 Jul-Aug;64(4):53–5.
- Beers MH, Berkow R, eds. Merck Manual Second Home Edition 2004–2005. “Clinical Manifestations of Liver Disease.” Available at: <http://www.merck.com/mmhe/sec10/ch135/ch135e.html?qt=portal%20hypertension&alt=sh>.
- Boigk G, Stroedter L, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. *Hepatology*. 1997 Sep;26(3):643–9.
- Buzzelli G, Moscarella S, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. *Int J Clin Pharmacol Ther Toxicol*. 1993 Sep;31(9):456–60.
- Chavali SR, Forse RA. Decreased production of interleukin-6 and prostaglandin E2 associated with inhibition of delta-5 desaturation of omega6 fatty acids in mice fed safflower oil diets supplemented with sesamol. *Prostaglandins Leukot Essent Fatty Acids*. 1999 Dec;61(6):347–52.
- Chen WJ, Yeh SL. Effects of fish oil in parenteral nutrition. *Nutrition*. 2003 Mar;19(3):275–9.
- Corrao G, Zambon A, et al. Nutrient intakes, nutritional patterns and the risk of liver cirrhosis: An explorative case-control study. *Eur J Epidemiol*. 2004;19(9):861–9.
- Dehmlow C, Erhard J, et al. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. *Hepatology*. 1996 Apr;23(4):749–54.
- Dias VC, Parsons HG. Modulation in delta 9, delta 6, and delta 5 fatty acid desaturase activity in the human intestinal CaCo-2 cell line. *J Lipid Res*. 1995 Mar;36(3):552–63.
- Di Sario A, Bendia E, et al. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. *Dig Liver Dis*. 2005 Nov;37(11):869–76.
- Feher J, Deak G, et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. *Orv Hetil*. 1989 Dec 17;130(51):2723–7.
- Ferenci P, Dragosics B, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol*. 1989 Jul;9(1):105–13.
- Fonda ML, Brown SG, et al. Concentration of vitamin B6 and activities of enzymes of B6 metabolism in the blood of alcoholic and nonalcoholic men. *Alcohol Clin Exp Res*. 1989 Dec;13(6):804–9.
- Glanze WD. *Mosby Medical Encyclopedia*. Revised ed. St. Louis, Mo: CV Mosby; 1996.
- Gopalan S, Saran S, et al. Practicalities of nutrition support in chronic liver disease. *Curr Opin Clin Nutr Metab Care*. 2000 May;3

(3):227-9. Review.

Gronn M, Christensen E, et al. Effects of dietary purified eicosapentaenoic acid (20:5 (n-3)) and docosahexaenoic acid (22:6(n-3)) on fatty acid desaturation and oxidation in isolated rat liver cells. *Biochim Biophys Acta*. 1992 Apr 8;1125(1):35-43.

Gruchow HW, Sobocinski KA, et al. Alcohol consumption, nutrient intake and relative body weight among US adults. *Am J Clin Nutr*. 1985 Aug;42(2):289-95.

Hirano T, Kaplowitz N, et al. Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. *Hepatology*. 1992 Dec;16(6):1423-7.

Hirsch S, Bunout D, et al. Controlled trial on nutrition supplementation in outpatients with symptomatic alcoholic cirrhosis. *J Parenter Enteral Nutr*. 1993 Mar-Apr;17(2):119-24.

Hirsch S, de la Maza MP, et al. Nutritional support in alcoholic cirrhotic patients improves host defenses. *J Am Coll Nutr*. 1999 Oct;18(5):434-41.

Ijuin H. Evaluation of pancreatic exocrine function and zinc absorption in alcoholism. *Kurume Med J*. 1998;45(1):1-5.

Kasper DL, Braunwald E, et al. *Harrison's Principles of Internal Medicine*. 16th ed. New York: McGraw-Hill Medical Publishing Division; 2005.

Kato M, Miwa Y, et al. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. *Intern Med*. 1998 May;37(5):429-34.

Kawase T, Kato S, et al. Lipid peroxidation and antioxidant defense systems in rat liver after chronic ethanol feeding. *Hepatology*. 1989 Nov;10(5):815-21.

Kravchenko LV, Avren'eva LI, et al. Effects of bioflavonoids on the toxicity of T-toxin in rats: A biochemical study. *Vopr Pitan*. 2000;69(5):20-3.

Leo MA, Rosman AS, et al. Differential depletion of carotenoids and tocopherol in liver disease. *Hepatology*. 1993 Jun;17(6):977-86.

Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. *Adv Pharmacol*. 1997;38:601-28.

Lieber CS. Alcohol: Its metabolism and interaction with nutrients. *Ann Rev Nutr*. 2000;20:395-430.

Lieber CS, Leo MA, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. *J Clin Gastroenterol*. 2003b Oct;37(4):336-9.

Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. *Alcohol*. 2002 Jul;27(3):173-7. Review.

Lieber CS, Robins SJ, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. *Gastroenterology*. 1994 Jan;106(1):152-9.

Lieber CS, Weiss DG, et al. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. *Alcohol Clin Exp Res*. 2003a Nov;27(11):1765-72.

Lumeng L. The role of acetaldehyde in mediating the deleterious effect of ethanol on pyridoxal 5'-phosphate metabolism. *J Clin Invest*. 1978 Aug;62(2):286-93.

Ma X, Zhao J, et al. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. *J Hepatol*. 1996 May;24(5):604-13.

Marchesini G, Bianchi G, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind, randomized trial. *Gastroenterology*. 2003 Jun;124(7):1792-801.

Marchesini G, Dioguardi FS, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy: A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. *J Hepatol.* 1990 Jul;11(1):92–101.

Mathurin P, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): Individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. *J Hepatol.* 2002 Apr;36(4):480–7.

Mato JM, Camara J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. *J Hepatol.* 1999 Jun;30(6):1081–9.

Melhem A, Stern M, et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial. *J Clin Gastroenterol.* 2005 Sep;39(8):737–42.

Mendenhall C, Roselle GA, et al. Relationship of protein calorie malnutrition to alcoholic liver disease: A reexamination of data from two Veterans Administration Cooperative Studies. *Alcohol Clin Exp Res.* 1995 Jun;19(3):635–41.

Mendenhall CL, Anderson S, et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. *Am J Med.* 1984 Feb;76(2):211–22.

Meng WC, Leung KL, et al. Prospective randomized control study on the effect of branched-chain amino acids in patients with liver resection for hepatocellular carcinoma. *Aust N Z J Surg.* 1999 Nov;69(11):811–5.

Nanji AA, French SW. Dietary linoleic acid is required for development of experimentally induced alcoholic liver injury. *Life Sci.* 1989b;44(3):223–7.

Nanji AA, Jokelainen K, et al. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. *J Pharmacol Exp Ther.* 2001 Nov;299(2):638–44.

Nanji AA, Khwaja S, et al. Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. *J Pharmacol Exp Ther.* 1994 Jun;269(3):1280–5.

Nanji AA, Mendenhall CL, et al. Beef fat prevents alcoholic liver disease in the rat. *Alcohol Clin Exp Res.* 1989a Feb;13(1):15–9.

Prakash S, Joshi YK. Assessment of micronutrient antioxidants, total antioxidant capacity and lipid peroxidation levels in liver cirrhosis. *Asia Pac J Clin Nutr.* 2004;13(Suppl):S110.

Rosenthal WS, Adham NF, et al. Riboflavin deficiency in complicated chronic alcoholism. *Am J Clin Nutr.* 1973 Aug;26(8):858–60.

Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver: A double-blind controlled study. *Scand J Gastroenterol.* 1982 Jun;17(4):517–21.

Shimizu S, Akimoto K, et al. Sesamin is a potent and specific inhibitor of delta 5 desaturase in polyunsaturated fatty acid biosynthesis. *Lipids.* 1991 Jul;26(7):512–6.

Speisky H, MacDonald A, et al. Increased loss and decreased synthesis of hepatic glutathione after acute ethanol administration: Turnover studies. *Biochem J.* 1985 Feb 1;225(3):565–72.

Utsunomiya T, Chavali SR, et al. Effects of sesamin-supplemented dietary fat emulsions on the ex vivo production of lipopolysaccharide-induced prostanoids and tumor necrosis factor alpha in rats. *Am J Clin Nutr.* 2000 Sep;72(3):804–8.

Van Aerde JE, Duerksen DR, et al. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. *Pediatr Res.* 1999 Feb;45(2):202–8.

Vendemiale G, Altomare E, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. *Scand J Gastroenterol.* 1989 May;24(4):407–15.

Wolf DC. Cirrhosis. eMedicine. Available at: [http:// www.emedicine.com/med/topic3183.htm](http://www.emedicine.com/med/topic3183.htm). Accessed January 16, 2006.

Yeh SL, Chang KY, et al. Effects of n-3 and n-6 fatty acids on plasma eicosanoids and liver antioxidant enzymes in rats receiving total parenteral nutrition. *Nutrition.* 1997 Jan;13(1):32–6.

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.